FINWIRES · TerminalLIVE
FINWIRES

AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer

By

Astrazeneca's (AZN) durvalumab, in combination with Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday.

Durvalumab's efficacy was evaluated in the Potomac study, a randomized, open-label, multi-center trial of 1,018 patients with high-risk NMIBC following transurethral resection of bladder tumor, according to the statement.

A statistically significant improvement in disease-free survival was observed with durvalumab plus BCG induction and maintenance compared with BCG induction and maintenance alone.

The recommended durvalumab dose for patients weighing at least 30 kilograms is 1,500 mg every four weeks for 13 cycles, in combination with BCG induction and maintenance treatment. Treatment should continue until disease recurrence, progression, unacceptable toxicity, or a maximum of 13 cycles.

Price: $184.89, Change: $-0.77, Percent Change: -0.41%

Related Articles

Wire

Dell Technologies Unit Wins $9.69 Billion US Navy Contract

Dell Technologies (DELL) unit Dell Federal Systems won a blanket purchase agreement with an overall estimated value of $9.69 billion from the US Navy under the Department of Defense Enterprise Software Initiative.The agreement will streamline software acquisition across the Defense Department, the intelligence community, and the US Coast Guard, according to a statement.The deal will allow clients to procure Microsoft (MSFT) software licenses, cloud subscriptions, and Software Assurance, according to the Department.

$DELL$MSFT
Wire

Dave to Replace American Woodmark in S&P SmallCap 600

Dave (DAVE) is set to replace American Woodmark (AMWD) in the S&P SmallCap 600 before trading begins Monday, S&P Dow Jones Indices said.MasterBrand (MBC) is acquiring American Woodmark in a deal expected to close May 29, the S&P Global (SPGI) unit said Wednesday in a statement.Dave shares rose 4.2% in after-hours trading.

$AMWD$DAVE$SPGI
Wire

Citi Trends Reports Preliminary Fiscal Q1 Sales, Lifts FY Comparable-Store Sales Outlook

Citi Trends (CTRN) reported fiscal Q1 preliminary sales late Wednesday of $230.9 million and raised its full-year outlook for comparable-store sales growth.A year earlier, sales were $201.7 million.Comparable-store sales growth in fiscal 2026 is expected to range from 8% to 10%, compared with the prior 5% to 7% forecast, the company said.Citi Trends also lifted its full-year adjusted EBITDA guidance to $35 million to $40 million from the previous outlook of $34 million to $38 million.Citi Trends shares rose 10% in after-hours trading.

$CTRN